About 77.5K results
Patritumab Deruxtecan Demonstrated Statistically Significant
Patritumab Deruxtecan Demonstrated Statistically Significant ...
Patritumab Deruxtecan Meets PFS End Point in Pretreated EGFR …
Patritumab Deruxtecan BLA Submission Receives Complete …
Patritumab Deruxtecan Granted Priority Review in the U.S. for
After FDA no, MSD/Daiichi post new data with lung cancer ADC
Patritumab deruxtecan extends PFS vs. chemotherapy in …
Daiichi Sankyo and MSD’s ADC improves progression-free survival …
- Some results have been removed